Gilead Sciences set aside $200 million for a potential settlement with federal prosecutors to resolve an investigation into ...

The CHMP recommends granting a marketing authorization to NVS' Fabhalta for the treatment of adults with C3 glomerulopathy, an ultra-rare, progressive kidney disease with no currently approved ...

Approximately one to two people per million worldwide are diagnosed with the ultra-rare kidney disease every year ...

M223, a preclinical drug for inflammatory diseases, with potential milestone payments of $777.5M plus royalties.

Basel: Novartis has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency ...

Xolair (omalizumab) shows superior efficacy and safety compared to multi-allergen oral immunotherapy in treating food ...

Discover how awareness and innovation are transforming breast cancer care, improving early detection, and offering hope for ...

Patients with three different food allergies who used omalizumab experienced better outcomes than patients who used multi-food oral immunotherapy, driven by lower rates of adverse events, according to ...

Pharmaceutical majors AstraZeneca and GSK have partnered with competitor Takeda and nine suppliers to accelerate the adoption ...

Additionally, preliminary results from Stage 3 of the OUtMATCH study provide early data on introducing allergenic foods into ...

Roche's Xolair outperformed oral immunotherapy in a Phase 3 trial for food allergies, showing better tolerance and fewer adverse events.

EMA committee recommends marketing approval for Novartis oral Fabhalta to treat adults living with C3 glomerulopathy: Basel Monday, March 3, 2025, 10:00 Hrs [IST] Novartis announc ...